EDGAR Filing Documents for 0001714899-24-000235

Form 4 - Statement of changes in beneficial ownership of securities:

SEC Accession No. 0001714899-24-000235

Filing Date

2024-11-27

Accepted

2024-11-27 16:44:42

Documents

Period of Report

2024-11-25

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 4	wk-form4_1732743876.html	4
1	FORM 4	wk-form4_1732743876.xml	4	7393
	Complete submission text file	0001714899-24-000235.txt		8891

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080

Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548

Denali Therapeutics Inc. (Issuer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O DENALI THERAPEUTICS INC. 151 OYSTER POINT BLVD., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080

Business Address

Ho Carole (Reporting) CIK: 0001724605 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38311 | Film No.: 241511978